Clinical Scorecard: Link Between Cytopenias Induced by Treatment and Clinical Outcomes in Lower-Risk Myelodysplastic Syndromes Following Imetelstat Therapy
At a Glance
Category
Detail
Condition
Lower-risk myelodysplastic syndromes (LR-MDS) with red blood cell transfusion-dependent anemia
Key Mechanisms
Imetelstat, a competitive telomerase inhibitor, induces early neutropenia and thrombocytopenia which correlate with hematologic response
Target Population
Adults with LR-MDS who are relapsed/refractory to or ineligible for erythropoiesis-stimulating agents
Imetelstat treatment leads to early grade 3/4 neutropenia (69%) and thrombocytopenia (61%), mostly within first 3 cycles, which are transient and manageable.
≥50% reduction in platelets within first 2 cycles is significantly associated with greater hemoglobin rise and higher rates of RBC transfusion independence.
≥75% reduction in neutrophils is associated with greater hemoglobin rise but not significantly with RBC transfusion independence.
Guideline-Based Recommendations
Diagnosis
Identify LR-MDS patients with RBC transfusion-dependent anemia relapsed/refractory or ineligible for ESAs.
Management
Administer imetelstat 7.1 mg/kg for eligible LR-MDS patients.
Monitor for early onset neutropenia and thrombocytopenia within first 2 treatment cycles.
Manage cytopenias with supportive care including platelet transfusions and myeloid growth factors as needed.
Monitoring & Follow-up
Regularly assess neutrophil and platelet counts, especially during first 4-5 weeks of therapy.
Observe for clinical consequences of cytopenias such as infections, bleeding, and febrile neutropenia.
Risks
Transient grade 3/4 neutropenia and thrombocytopenia with low incidence of severe infections (<4%), bleeding (<1%), and febrile neutropenia (3%).
Potential need for platelet transfusions and myeloid growth factor support.
Patient & Prescribing Data
226 adults with LR-MDS and RBC transfusion-dependent anemia treated with imetelstat in Phase II/III and QTc studies.
Early cytopenias correlate with improved hematologic outcomes; platelet reduction ≥50% predicts higher likelihood of hemoglobin improvement and RBC transfusion independence.
Clinical Best Practices
Anticipate and monitor for early grade 3/4 neutropenia and thrombocytopenia during imetelstat therapy.
Use early platelet and neutrophil count reductions as potential biomarkers for treatment response.
Provide supportive care promptly to manage cytopenias and minimize clinical complications.
Educate patients about transient nature of cytopenias and low risk of severe adverse events.
by Amer M. Zeidan, Valeria Santini, María Díez-Campelo, Michael R. Savona, Mikkael A. Sekeres, Yazan F. Madanat, Pierre Fenaux, Azra Raza, Moshe Mittelman, Sylvain Thépot, Rena Buckstein, Ulrich Germing, David Valcárcel, Anna Jonášová, Sheetal Shah, Qi Xia, Libo Sun, Shyamala Navada, Tymara Berry, Uwe Platzbecker, Rami S. Komrokji
